VA Pushes Psychedelic Therapy for 2.1 Million Veterans Amid Rising Suicide Concerns

Key points

• Andrew Gradison, a senior VA adviser, stated that up to 2.1 million veterans with mental illnesses could benefit from psychedelic treatments.
• President Trump issued an executive order in April 2026 to accelerate research, clinical trials, and patient access to these substances.
• The 2026 VA Annual Veterans Suicide Prevention Report recorded 6,488 veteran suicides in 2024, averaging 17.7 per day.
• 62% of veterans who died by suicide in 2024 were not receiving VA healthcare in the year of their death or the year prior.
• The VA has expanded enrollment by 19.5% since 2001, reaching 50.1% of eligible veterans in 2024, and launched campaigns to identify at-risk individuals.

Background

This policy shift follows the Trump administration’s broader efforts to address veteran welfare, including the rapid acceleration of Camp Lejeune water contamination settlements, which reached a $1 billion milestone in October 2026. Previous coverage also noted legal challenges regarding the administration’s proposed 250-foot arch in Washington, D.C., reflecting ongoing debates over executive actions affecting veteran communities. The current focus on psychedelic therapy represents a significant departure from the Biden administration’s stance, where the FDA rejected MDMA for PTSD treatment in 2024.

How outlets are covering it

Politico highlights the political alignment between the Trump administration and Republican-backed psychedelic advocacy, noting that veterans are disproportionately Republican. KOMU 8 and The Clarion emphasize the human cost of veteran suicide, with KOMU 8 featuring a display of 44 combat boots to represent daily suicide deaths and The Clarion stressing the need for community-based prevention beyond clinical settings. The Clermont Sun provides detailed statistical analysis from the 2026 VA report, noting that while suicide rates dropped for VA-enrolled veterans, they rose for unenrolled veterans. All sources agree on the severity of the mental health crisis but differ in focus: Politico centers on policy and drug access, while KOMU 8 and The Clarion focus on stigma and community support, and The Clermont Sun focuses on enrollment gaps and statistical trends.

Why it matters

The move to integrate psychedelics into VA care could redefine mental health treatment for millions of veterans, potentially addressing conditions like PTSD and depression that traditional therapies have not fully resolved. However, the lack of FDA approval for these substances raises questions about safety and efficacy. Simultaneously, the high rate of suicide among unenrolled veterans underscores the need for broader access to care, suggesting that policy changes must address both treatment innovation and enrollment barriers to effectively reduce veteran suicide rates.

What to watch

The VA is expected to expand its capacity to provide psychedelic treatments as part of the executive order’s goals. Continued efforts to enroll unenrolled veterans in the VA system will be critical, as 62% of suicide victims in 2024 were not receiving VA care. The administration may face scrutiny over the safety and efficacy of psychedelics, given the lack of regulatory approval, while community-based prevention initiatives will likely gain traction to address the stigma surrounding mental health among veterans.